The PREPAIRD Study: Personalized Surveillance for Early Detection of Pancreatic Cancer in High Risk Individuals

NAEnrolling by invitationINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

September 1, 2022

Primary Completion Date

December 31, 2042

Study Completion Date

December 31, 2042

Conditions
Hereditary Pancreatic Cancer
Interventions
OTHER

Annual surveillance

Annual surveillance includes annual MRI and/or an assessment new onset diabetes and unintended weight loss.

Trial Locations (1)

Unknown

Oslo University Hospital, Oslo

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Helse Sor-Ost

OTHER_GOV

collaborator

University of Oslo

OTHER

collaborator

Haukeland University Hospital

OTHER

collaborator

St. Olavs Hospital

OTHER

collaborator

Helse Stavanger HF

OTHER_GOV

collaborator

University of Bergen

OTHER

collaborator

Immunovia, Inc.

INDUSTRY

collaborator

University Hospital of North Norway

OTHER

lead

Oslo University Hospital

OTHER